Enzyme by Design

Dr. Amanda Schalk of University of Illinois Chicago develops new and improved cancer-fighting enzymes. Our bodies already employ cancer-fighting proteins. Dr. Schalk engineers ways to make those proteins more effective with fewer side effects.

Dr. Schalk is co-founder of Enzyme by Design which improves existing enzyme-based therapies for blood and solid tumors. Using biomarkers and , they can predict which enzyme therapies will be most successful.

Want to learn more about what's happening in Chicago's biotech ecosystem? Contact Jonathan Metzl Cushman & Wakefield for the full report: https://www.cushmanwakefield.com/en/united-states/insights/us-articles/chicago-life-sciences-next-frontier

is super excited to have two of our scientist co-founders represented at for the
awards! Go translational science!

Meet the 40 under 40 Chicago Scientists - Translation | Halo Blog Meet the 40 under 40 Chicago scientists dedicated to translating research into real-world applications.

Enzyme by Design covered by Crain's Business today!

Cancer-sniffing dogs home in on biomarkers • UIC startup gets funds to lessen impact of chemo • Lurie, Advocate children’s hospitals on U.S. News list Breadcrumb Home Health Pulse June 19, 2019 05:15 AM Cancer-sniffing dogs home in on biomarkers • UIC startup gets funds to lessen impact of chemo • Lurie, Advocate children’s hospitals on U.S. News list Jon Asplund Tweet Share Share Email More Print Getty Images USING DOGS TO IDENTIFY CANCER C...

Enzyme by Design featured in UIC Today.

UIC startup raises nearly $1M to help develop safer leukemia chemotherapy | UIC Today Enzyme by Design, a startup company founded by UIC researchers in the department of biochemistry and molecular genetics, recently has secured nearly $1 million in total funding to help it further develop a less toxic version of chemotherapy commonly used to treat acute lymphoblastic leukemia, the mo...

Great article about Enzyme by Design by University of Illinois Cancer Center.

Company throws perfect pitch at investing conference - University of Illinois Cancer Center A small company is working on a big discovery. Enzyme By Design (EbD), a University of Illinois at Chicago spinoff formed out of research conducted in the laboratory of University of Illinois Cancer Center member Arnon Lavie, professor of biochemistry and molecular genetics, is developing a chemothe...

Our CEO and captain won best in Biopharma Pitch at MedCity Invest in May

Here are the winners from 2019’s MedCity INVEST Pitch Perfect Contest This year's edition of the Pitch Perfect competition involved dozens of live pitches at the MedCity News INVEST conference in Chicago. Here are the startups who came out on top.